Search results
Results from the WOW.Com Content Network
In a statement on Friday, the two partners said Jardiance cut the risk of kidney disease progression and cardiovascular death by 28%, citing results from a late-stage trial which included people ...
Common side effects include hyperventilation, anorexia, abdominal pain, nausea, vomiting, lethargy, mental status changes, hypotension, acute kidney injury, and vaginal yeast infections. [2] Rarer but more serious side effects include a skin infection of the groin called Fournier's gangrene and a form of diabetic ketoacidosis with normal blood ...
A new study compares the benefits and risks of taking GLP-1 medications for weight loss, including risks of dementia, addiction, heart disease, and gastrointestinal problems, among others.
Kidney toxicity [5] associated with kidney failure; associated with development of cancer, particularly of the urinary tract, known carcinogen [8] [9] Atractylate Atractylis gummifera: Liver damage, [3] nausea, vomiting, epigastric and abdominal pain, diarrhoea, anxiety, headache and convulsions, often followed by coma [10]
Sotagliflozin (Inpefa) is a dual SGLT1/SGLT2 inhibitor approved by the US Food and Drug Administration (FDA) in May 2023, to reduce the risk of cardiovascular death, hospitalization for heart failure, and urgent heart failure visit in adults with heart failure or type 2 diabetes, chronic kidney disease, and other cardiovascular risk factors ...
In the trial, Jardiance cut the combined risk of cardiovascular death or hospitalization from heart failure in HFpEF patients with or without diabetes. At the 26-month mark, 13.8% of Jardiance ...
Nephrotoxicity is toxicity in the kidneys. It is a poisonous effect of some substances, both toxic chemicals and medications, on kidney function. [1] There are various forms, [2] and some drugs may affect kidney function in more than one way. Nephrotoxins are substances displaying nephrotoxicity.
Novo Nordisk's Wegovy obesity drug reduced adverse kidney-related events by 22% in overweight and obese people in a large study, according to a new analysis the Danish drugmaker published on Saturday.